%PDF-1.4
%
126 0 obj
<>
endobj
281 0 obj
<>/Font<>>>/Fields[]>>
endobj
123 0 obj
<>
endobj
299 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-26T13:16:45Z
2024-03-29T05:50:17-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T05:50:17-07:00
application/pdf
Heather
990530.june
uuid:1599e2bc-1dd2-11b2-0a00-4708276d7200
uuid:1599e2c3-1dd2-11b2-0a00-b80000000000
endstream
endobj
112 0 obj
<>
endobj
113 0 obj
<>
endobj
127 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
35 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
58 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
81 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
99 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
102 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
338 0 obj
[343 0 R]
endobj
339 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 71 714.5293 Tm
(Res 1998;24:67-71.)Tj
-1.25 -1.25 Td
[(4.)-500 (Sakane )18 (T)74 (, Suzuki N, Hirose )37 (Y)129 (, et al. Mechanisms of KE-298, )]TJ
1.25 -1.25 Td
(2-acetylthiomethyl-4-\(4-methylphenyl\)-4-oxobutanoic acid, to)Tj
0 -1.25 TD
(suppress abnormal synovial cell functions in patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1997;24:2213-20.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(5.)-500 (Nagai H, )18 (T)70 (akaoka )37 (Y)129 (, Mori H, Kawada K. Ef)18 (fect of KE-298 on)]TJ
0 Tc 1.25 -1.25 Td
(experimental arthritis in mice. Pharmacology 1996;53:190-6.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(6.)-500 (Kameo K, )18 (T)70 (akeshita K, )37 (Y)100 (asuda )37 (Y)129 (, Matsumoto K, )18 (T)70 (omisawa K.)]TJ
0 Tc 1.25 -1.25 Td
(Preparation and antirheumatic activity of optically active )Tj
T*
(2-acetylthiomethyl-4-\(4-methylphenyl\)-4-oxobutanoic acid )Tj
T*
(\(KE-298\). Chem Pharm Bull 1996;44:602-4.)Tj
-1.25 -1.25 Td
[(7.)-500 (Hashimoto M, Kobayashi K, )37 (Y)100 (amagata N, et al. Suppression of)]TJ
1.25 -1.25 Td
(pulmonary granulomatous inflammation by immunomodulating)Tj
-0.02991 Tw T*
[(agents. Agents Actions )-55 (1992;37:99-106.)]TJ
-0.00011 Tc 0.02499 Tw -1.25 -1.25 Td
[(8.)-500 (Forstermann U, Gath I, Schwarz P)111 (, Closs EI, Kleinert H. Isoforms of)]TJ
0 Tc 1.25 -1.25 Td
(nitric oxide synthase. Properties, cellular distribution and)Tj
T*
(expressional control. Biochem Pharmacol 1995;50:1321-32.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(9.)-500 (Borderie D, Hilliquin P)111 (, Hernvann )55 (A, Kahan )55 (A, Menkes CJ,)]TJ
0 Tc 1.25 -1.25 Td
(Ekindjian OG. Nitric oxide synthase is expressed in the)Tj
T*
(lymphomononuclear cells of synovial fluid in patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1999;26:2083-8.)Tj
-1.75 -1.25 Td
[(10.)-500 (Clancy RM, )55 (Amin )55 (AR, )55 (Abramson SB. )18 (The role of nitric oxide in)]TJ
1.75 -1.25 Td
[(inflammation and immunity)65 (. )55 (Arthritis Rheum 1998;41:1)37 (141-51.)]TJ
-1.7131 -1.25 Td
[(1)37 (1.)-500 (Ialenti )55 (A, Moncada S, Rosa MD. Modulation of adjuvant arthritis by)]TJ
1.7131 -1.25 Td
[(endogenous nitric oxide. Br J Pharmacol 1993;1)37 (10:701-6.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(12.)-500 (Cannon GW)92 (, Openshaw SJ, Hibbs JB, Hoidal JR, Huecksteadt )18 (TP)111 (,)]TJ
0 Tc 1.75 -1.25 Td
[(Grif)18 (fiths MM. Nitric oxide production during adjuvant-induced and)]TJ
T*
[(collagen-induced arthritis. )55 (Arthritis Rheum 1996;39:1677-84.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(13.)-500 (Stefanovic-Racic M, Meyers K, Meschter C, Cof)18 (fey JW)92 (, Hof)18 (fman)]TJ
0 Tc 1.75 -1.25 Td
[(RA, Evans CH. N-monomethyl ar)18 (ginine, an inhibitor of nitric oxide)]TJ
T*
(synthase, suppresses the development of adjuvant arthritis in rats.)Tj
T*
(Arthritis Rheum 1994;37:1062-9.)Tj
-1.75 -1.25 Td
[(14.)-500 (Connor JR, Manning PT)74 (, Settle SL, et al. Suppression of adjuvant-)]TJ
1.75 -1.25 Td
(induced arthritis by selective inhibition of inducible nitric oxide)Tj
T*
(synthase. Eur J Pharmacol 1995;273:15-24.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(15.)-500 (Kameo K, Ogawa K, )18 (T)70 (akeshita K, Nakaike S, )18 (T)70 (omisawa K, Sota K.)]TJ
0 Tc 1.75 -1.25 Td
(Studies on anti-rheumatic agents: 3-Benzoylpropionic acid)Tj
T*
(derivatives. Chem Pharm Bull 1988;36:2050-60.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(16.)-500 (Rockett KA, )55 (A)92 (wburn MM, Cowden )18 (WB, Clark IA. Killing of)]TJ
0 Tc 1.75 -1.25 Td
(Plasmodium falciparum in vitro by nitric oxide derivatives. Infect)Tj
T*
(Immun 1991;59:3280-3.)Tj
-1.75 -1.25 Td
[(17.)-500 (Amin )55 (AR, )55 (Attur MG, )18 (Thakker GD, et al. )55 (A)-220 (novel mechanism of)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(action of tetracyclines: Ef)18 (fects on nitric oxide synthases. Proc Natl)]TJ
0 Tc T*
[(Acad Sci USA)-220 (1996;93:14014-9.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(18.)-500 (Barber SA, Fultz MJ, Salkowski CA, )18 (V)129 (ogel SN. Dif)18 (ferential)]TJ
1.75 -1.25 Td
(expression of interferon regulatory factor 1 \(IRF-1\), IRF-2, and)Tj
0 Tc T*
(interferon consensus sequence binding protein gene in)Tj
-0.00011 Tc T*
(lipopolysaccharide \(LPS\)-responsive and LPS-hyporesponsive)Tj
0 Tc T*
(macrophages. Infect Immun 1995;63:601-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(19.)-500 (Schreiber E, Matthias P)111 (, Muller EE, Schaf)18 (fner )18 (W)92 (. Rapid detection of)]TJ
1.75 -1.25 Td
(octamer binding proteins with \221mini-extracts\222, prepared from a sma\
ll)Tj
0 Tc T*
[(number of cells. Nucleic )55 (Acids Res 1989;17:6419.)]TJ
-1.75 -1.25 Td
[(20.)-500 (Church GM, Gilbert )18 (W)92 (. Genomic sequencing. Proc Natl )55 (Acad Sci)]TJ
-0.00011 Tc 0 Tw 1.75 -1.25 Td
[(USA)-220 (1984;81:1991-5.)]TJ
0 Tc 0.0249 Tw -1.75 -1.25 Td
[(21.)-500 (Saito S, Matsuura M, )18 (T)70 (ominaga K, Kirikae )18 (T)74 (, Nakano M. Important)]TJ
1.75 -1.25 Td
(role of membrane-associated CD14 in the induction of IFN-\337 and)Tj
T*
(subsequent nitric oxide production by murine macrophages in)Tj
T*
(response to bacterial lipopolysaccharide. Eur J Biochem)Tj
0 Tw T*
(2000;267:37-45.)Tj
0.02499 Tw -1.75 -1.25 Td
[(22.)-500 (W)80 (eisz )55 (A, Cicatiello L, Esumi H. Regulation of the mouse inducible-)]TJ
1.75 -1.25 Td
(type nitric oxide synthase gene promoter by interferon-)Tj
/T1_0 1 Tf
0 Tw 22.249 0 Td
(\t)Tj
/TT0 1 Tf
0.02499 Tw [0.1 (, bacterial)]TJ
-22.249 -1.25 Td
[(lipopolysaccharide and MG-monomethyl- L-ar)18 (ginine. Biochem J)]TJ
0 Tw T*
(1996;316:209-15.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(23.)-500 (Delgado M, Munoz-Elias EJ, Gomariz RP)111 (, Ganea D. )18 (V)111 (asoactive)]TJ
0 Tc 1.75 -1.25 Td
(intestinal peptide and pituitary adenylate cyclase-activating)Tj
33 80 Td
(polypeptide prevent inducible nitric oxide synthase transcription in)Tj
T*
(macrophage by inhibiting NF-kB and IFN regulatory factor 1)Tj
T*
(activation. J Immunol 1999;162:4685-96.)Tj
-1.75 -1.25 Td
[(24.)-500 (Y)100 (amashita M, Niki H, )37 (Y)100 (amada M, Mue S, Ohuchi K. Induction of)]TJ
1.75 -1.25 Td
(nitric oxide synthase by lipopolysaccharide and its inhibition by)Tj
T*
[(auranofin in RA)80 (W264.7 cells. Eur J Pharmacol 1997;338:151-8.)]TJ
-1.75 -1.25 Td
[(25.)-500 (Amin )55 (AR, )18 (V)111 (yas P)111 (, )55 (Attur MG, et al. )18 (The mode of action of aspirin-)]TJ
1.75 -1.25 Td
[(like drugs: Ef)18 (fect on inducible nitric oxide synthase. Proc Natl )55 (Acad)]TJ
-0.00011 Tc T*
[(Sci USA)-220 (1995;92:7926-30.)]TJ
0 Tc -1.75 -1.25 Td
[(26.)-500 (Jeon KI, Jeong JY)129 (, Jue DM. )18 (Thiol-reactive metal compounds inhibit)]TJ
1.75 -1.25 Td
(NF-kB activation by blocking IkB kinase. J Immunol)Tj
0 Tw T*
(2000;164:5981-9.)Tj
0.0249 Tw -1.75 -1.25 Td
[(27.)-500 (Chen )37 (YC, )37 (Y)100 (ang LL, Lee )18 (TFJ. Oroxylin )55 (A)-220 (inhibition of)]TJ
1.75 -1.25 Td
(lipopolysaccharide-induced iNOS and COX-2 gene expression via)Tj
T*
[(suppression of nuclear factor)20 (-kB activation. Biochem Pharmacol)]TJ
0 Tw T*
(2000;59:1445-57.)Tj
0.0249 Tw -1.75 -1.25 Td
[(28.)-500 (D\222acquisto F)80 (, Lanzotti )18 (V)129 (, Carnuccio R. Cyclolinteinone, a)]TJ
-0.00011 Tc 1.75 -1.25 Td
(sesterterpene from sponge Cacospongia linteiformis, prevents)Tj
0 Tc T*
(inducible nitric oxide synthase and inducible cyclo-oxygenase)Tj
T*
[(protein expression by blocking nuclear factor)20 (-kB activation in J774)]TJ
T*
(macrophages. Biochem J 2000;346:793-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(29.)-500 (Xie QW)92 (, Kashiwabara )37 (Y)129 (, Nathan C. Role of transcription factor NF-)]TJ
0 Tc 1.75 -1.25 Td
(kB/Rel in induction of nitric oxide synthase. J Biol Chem)Tj
0 Tw T*
(1994;269:4705-8.)Tj
0.02499 Tw -1.75 -1.25 Td
[(30.)-500 (Nathan C, Xie QW)92 (. Nitric oxide synthases: Roles, tolls and controls.)]TJ
1.75 -1.25 Td
(Cell 1994;78:915-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(31.)-500 (T)70 (suji F)80 (, Miyake )37 (Y)129 (, )55 (Aono H, Kawashima )37 (Y)129 (, Mita S. Ef)18 (fects of)]TJ
0 Tc 1.75 -1.25 Td
(bucillamine and N-acetyl-L-cysteine on cytokine production and)Tj
T*
[(collagen-induced arthritis. Clin Exp Immunol 1999;1)37 (15:26-31.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(32.)-500 (Fujisawa K, )55 (Aono H, Hasunuma )18 (T)74 (, )37 (Y)100 (amamoto K, Mita S, Nishioka)]TJ
0 Tc 1.75 -1.25 Td
[(K. )55 (Activation of transcription factor NF-kB in human synovial cells)]TJ
-0.00011 Tc T*
(in response to tumor necrosis factor )Tj
/T1_0 1 Tf
0 Tc 0 Tw 14.6996 0 Td
(\005)Tj
/TT0 1 Tf
-0.02991 Tw [0.2 (. Arthritis )-55 (Rheum )-55 (1996;)]TJ
0 Tw -14.6996 -1.25 Td
(39:197-203.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(33.)-500 (Chandra )55 (A, Demirhan I, )55 (Arya SK, Chandra P)111 (. D-penicillamine)]TJ
0 Tc 1.75 -1.25 Td
(inhibits transactivation of human immunodeficiency virus type-1)Tj
T*
[(L)92 (TR by transactivator protein. FEBS Lett 1988;236:282-6.)]TJ
-1.75 -1.25 Td
[(34.)-500 (Y)100 (ang JP)111 (, Merin JP)111 (, Nakano )18 (T)74 (, Kato )18 (T)74 (, Kitade )37 (Y)129 (, Okamoto )18 (T)74 (.)]TJ
1.75 -1.25 Td
(Inhibition of the DNA-binding activity of NF-kB by gold)Tj
T*
(compounds in vitro. FEBS Lett 1995;361:89-96.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(35.)-500 (Amin )55 (AR, Patel RN, )18 (Thakker GD, Lowenstein CJ, )55 (Attur MG,)]TJ
0 Tc 1.75 -1.25 Td
(Abramson SB. Post-transcriptional regulation of inducible nitric)Tj
T*
[(oxide synthase mRNA)-220 (in murine macrophages by doxycycline and)]TJ
T*
(chemically modified tetracyclines. FEBS Lett 1997;410:259-64.)Tj
-1.75 -1.25 Td
[(36.)-500 (V)129 (odovots )37 (Y)129 (, Bogdan C, Paik J, Xie QW)92 (, Nathan CF)80 (. Mechanisms of)]TJ
-0.00011 Tc 1.75 -1.25 Td
(suppression of macrophage nitric oxide release by transforming)Tj
0 Tc T*
(growth factor \337. J Exp Med 1993;178:605-13.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(37.)-500 (Kunz D, )18 (W)80 (alker G, Eberhardt )18 (W)92 (, Pfeilschifter J. Molecular)]TJ
0 Tc 1.75 -1.25 Td
(mechanisms of dexamethasone inhibition of nitric oxide synthase)Tj
T*
(expression in interleukin 1\337-stimulated mesangial cells: Evidence for\
)Tj
T*
(the involvement of transcriptional and posttranscriptional regulation.)Tj
-0.00011 Tc T*
[(Proc Natl )55 (Acad Sci USA)-220 (1996;93:255-9.)]TJ
-1.75 -1.25 Td
[(38.)-500 (Gao JJ, Filla MB, Fultz MJ, )18 (V)129 (ogel SN, Russell SW)92 (, Murphy )18 (WJ.)]TJ
1.75 -1.25 Td
(Autocrine/paracrine IFN-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.4 (\005)]TJ
/TT0 1 Tf
0.02499 Tw [0.1 (\337 mediates the lipopolysaccharide-)]TJ
T*
(induced activation of transcription factor stat1a in mouse)Tj
T*
(macrophage: Pivotal role of stat1a in induction of the inducible)Tj
T*
(nitric oxide synthase gene. J Immunol 1998;161:4803-10.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(39.)-500 (Goldring CEP)111 (, Reveneau S, )55 (Aigarte M, Jeannin JF)80 (. In vivo foot-)]TJ
0 Tc 1.75 -1.25 Td
(printing of the mouse inducible nitric oxide synthase gene: inducible)Tj
T*
(protein occupation of numerous sites including Oct and NF-IL6.)Tj
T*
[(Nucleic )55 (Acids Res 1996;24:1682-7.)]TJ
-1.75 -1.25 Td
[(40.)-500 (van de Loo F)74 (A, )55 (Arntz OJ, van Enckevort FH, van Lent PL, van den)]TJ
1.75 -1.25 Td
[(Ber)18 (g )18 (WB. Reduced cartilage proteoglycan loss during zymosan-)]TJ
T*
(induced gonarthritis in NOS2-deficient mice and in anti-interleukin-)Tj
T*
[(1-treated wild-type mice with unabated joint inflammation. )55 (Arthritis)]TJ
T*
(Rheum 1998;41:634-46.)Tj
ET
0 0 0 0 scn
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
0.0249 Tw 8 0 0 8 54.5 35.9844 Tm
[(Inoue, et al: KE-758 suppr)37 (esses NO and iNOS)]TJ
0 Tw 60.9375 -0.0313 Td
(1237)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 58.15 407.5 -10.83 re
f*
0.5 w
102.25 58.15 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
149 0 obj
<>
endobj
170 0 obj
<>
endobj
304 0 obj
<>
endobj
135 0 obj
<>
endobj
131 0 obj
<>
endobj
129 0 obj
<>
endobj
164 0 obj
<>stream
HVpMg}9ބ(yȃsHIn\tBEo^yH)0EF-]֎mCV);^k:;-x3;{}
P?լn~lJG*zN
UER
)VځH s̅
cΔ^=xKӳÚ|:|K&F̜]ߨN*"{oG{}VfùL/zU̞7ߺC
fsK*~Ʉ(uNeUʑXHHB
wL?4SB-~,"F=:#CXO0"<
XNHPV8R:Q^J!ezu,YXࠬN+> XkeD973R5g5bG9q?uy9"-p"RtD#x ;.!Zs`GUXDv d9_WvFk\
/hjYVBC
:ҧ?3$LC
3q
(WbPWq+˕jѺdVEfNԽЗ'b
y5:b"At"Ol)%Y*g˃{UQWWa$p=| Fpno"HDk[n-}}8\D#ЄSD"_!-!ˋJ2@ThPM
93:&q1sdwX±c> ێq/qy7wp(DGHHnVm /ƈJXT%b!ߋ]q*}r\$W=<-M(.:TnӢ)ZVmw|t'+Zhr2trZVUi-6ZJF5a#I(B)f7Xuf)O,av'~C:y$ȵOp]'H!%(^úLk]
=H]huVӭZ5{߈cFQ?(<ŀ[.Y/33_bZj'W.c qھ&ut-"#MU@4ÆmPxF7uYeleSɘc|MI;(4{-5Տ5OO.؟bfDړ1qme}L?%au D6E$(ZJRleLW&>fGo䢼N+ڧ/\n"R<IRHIIIY%U1FΉL